ImmunityBio
PublicImmunityBio is now publicly traded
The data on this page reflects ImmunityBio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Post-IPO Financing
Mar 31, 2026
Total Funding Raised
$100M
Company Overview
ImmunityBio (NAS: IBRX) is a biotechnology company specializing in the discovery, development, and commercialization of advanced immuno- and cellular therapies that enhance the natural immune system to promote sustained immune responses.
Sector
Healthcare
AI Layer
Non-AI
Keywords
ImmunityBio Comparables
Compare ImmunityBio with similar companies based on industry and business-model similarity.
No public comparables are available for ImmunityBio. Request access to learn about comparables coverage.
Request accessImmunityBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Post-IPO Financing | Mar 31, 2026 |
ImmunityBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Nant Capital, LLC | Post-IPO Financing |
| Oberland Capital Management | Post-IPO Financing |
ImmunityBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access